Cognito Therapeutics HOPE pivotal trial: design and rationale for 670-patient Spectris RCT in mild-to-moderate Alzheimer's disease
Summary
The HOPE study (NCT05637801) represents the pivotal efficacy trial of Spectris gamma entrainment therapy for Alzheimer's disease, building on the OVERTURE feasibility study that provided mechanistic validation (corpus callosum preservation, EEG slowing attenuation, brain volume maintenance) without being powered for statistical efficacy. HOPE enrolls approximately 670 patients with mild-to-moderate Alzheimer's randomized to 12 months of daily Spectris or sham sensory stimulation. The primary endpoint is a composite cognitive and functional measure. The trial uses the Alzheimer's Disease Composite Score (ADCOMS) — a sensitive composite capturing cognition, daily function, and clinician assessment changes in mild AD. Top-line data expected 2026.
Why it matters
The HOPE trial design choices reflect the lessons of every prior failed AD trial: 670 patients to ensure statistical power, 12 months to detect meaningful change, a composite endpoint sensitive to early AD progression, and a sham control that matches daily Spectris use without the active stimulation. The sham-controlled design answers the placebo question that OVERTURE couldn't — if 670 patients on active Spectris outperform 670 on sham on a composite cognitive and functional endpoint, the treatment effect is real and attributable to the 40Hz gamma mechanism specifically.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial